Results 141 to 150 of about 50,884 (170)
Evaluating the Risk of Hypophosphatemia with Ferric Carboxymaltose and the Recommended Approaches for Management: A Consensus Statement [PDF]
Journal of Clinical MedicineBackground/Objectives: The development of hypophosphatemia has been associated with intravenous iron products, with the rate of hypophosphatemia found to be higher with ferric carboxymaltose.
Justin Ezekowitz +2 more
exaly +4 more sources
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial [PDF]
Lancet, The, 2020 Background Intravenous ferric carboxymaltose has been shown to improve symptoms and quality of life in patients with chronic heart failure and iron deficiency.
Tim Friede +2 more
exaly +7 more sources
Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose [PDF]
Journal of Perinatal Medicine, 2012 Oral iron substitution has shown to be insufficient for treatment of severe iron deficiency anemia in pregnancy. Ferric carboxymaltose is a new intravenous (i.v.) iron formulation promising to be more effective and as safe as iron sucrose.
Begoña Martinez de Tejada +2 more
exaly +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Revista Espanola De Cardiologia (English Ed ), 2015 INTRODUCTION AND OBJECTIVES Treatment with ferric carboxymaltose improves symptoms, functional capacity, and quality of life in patients with chronic heart failure and iron deficiency.
Florian S Gutzwiller +2 more
exaly +2 more sources
Ferric Carboxymaltose (FCM)–Associated Hypophosphatemia (HPP): A Systematic Review [PDF]
American Journal of HematologyKenneth R Carson, William J Hrushesky
exaly +2 more sources